Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Yi Wen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA (Drs Wen, Li, Smith, Lin, Chen, Bellinger, Zhen, Beyer, Siegel, Qian, Ruoto…. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Apolipoprotein A-V. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
BACKGROUND: Cholesteryl ester transfer protein (CETP) mediates the exchange of triglycerides (TG) from apolipoprotein B (ApoB)-containing lipoproteins to high-density lipoproteins (HDL) and the reciprocal exchange of cholesterol (C) from HDL to ApoB-containing lipoproteins. CETP inhibition increases HDL-C and decreases low-density lipoprotein cholesterol (LDL-C) while modestly decreasing TG. Considering that CETP inhibitors block removal of TG from TG-rich lipoproteins (TRL), it is interesting that CETP inhibition decreases TG concentrations. TG levels are largely regulated by lipoprotein lipase (LPL), the enzyme primarily responsible for hydrolyzing TG. The angiopoietin-like 3/8 complex (ANGPTL3/8) is the most potent circulating LPL inhibitor, while the TG-lowering apolipoprotein A5 (ApoA5) acts by suppressing ANGPTL3/8-mediated LPL inhibition. METHODS: To better understand CETP biology, we studied the effects of CETP overexpression and CETP inhibition on the levels of ANGPTL3/8 and ApoA5 in circulation using dedicated immunoassays. RESULTS: CETP-overexpressing transgenic mice had increased TG and normal ANGPTL3/8 levels but manifested dramatically reduced ApoA5 concentrations. Administration of the CETP inhibitor evacetrapib had no effect on ANGPTL3/8 levels in CETP-overexpressing mice or in humans. However, evacetrapib administration increased ApoA5 concentrations in both species. In human subjects, evacetrapib treatment increased circulating ApoA5 levels in the late-stage ACCELERATE and ACCENTUATE studies by 160.1% and 204.7%, respectively. CONCLUSIONS: Our results uncover a previously unrecognized link between CETP and ApoA5 by showing that CETP overexpression reduces ApoA5 levels while CETP inhibition increases ApoA5 concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA (Drs Wen, Li, Smith, Lin, Chen, Bellinger, Zhen, Beyer, Siegel, Qian, Ruotolo, and Konrad).
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA (Drs Wen, Li, Smith, Lin, Chen, Bellinger, Zhen, Beyer, Siegel, Qian, Ruotolo, and Konrad). Electronic address: konrad_robert@lilly.com.
Förderung
- Eli Lilly and Company
Zitieren
APA
Wen, Y., Li, H., Smith, S., Lin, Y., Chen, Y. Q., Bellinger, M., Zhen, E. Y., Beyer, T. P., Siegel, R. W., Qian, Y., Ruotolo, G., & Konrad, R. J. (2025). Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.06.008
Vancouver
Wen Y, Li H, Smith S, Lin Y, Chen YQ, Bellinger M, et al. Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.06.008
BibTeX
@article{Wen2025,
author = {Wen, Yi and Li, Hongxia and Smith, Sydney and Lin, Yanzhu and Chen, Yan Q and Bellinger, Melissa and Zhen, Eugene Y and Beyer, Thomas P and Siegel, Robert W and Qian, Yuewei and Ruotolo, Giacomo and Konrad, Robert J},
title = {Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.06.008}
}
EUVIMED